181 related articles for article (PubMed ID: 14637073)
1. Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease.
Morelli M
Exp Neurol; 2003 Nov; 184(1):20-3. PubMed ID: 14637073
[No Abstract] [Full Text] [Related]
2. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
Chen JF
Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Opportunities for Caffeine and A2A Receptor Antagonists in Retinal Diseases.
Boia R; Ambrósio AF; Santiago AR
Ophthalmic Res; 2016; 55(4):212-8. PubMed ID: 26959995
[TBL] [Abstract][Full Text] [Related]
4. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.
Schwarzschild MA; Chen JF; Ascherio A
Neurology; 2002 Apr; 58(8):1154-60. PubMed ID: 11971080
[TBL] [Abstract][Full Text] [Related]
5. Do caffeine and more selective adenosine A
Chen JF; Schwarzschild MA
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
[TBL] [Abstract][Full Text] [Related]
6. The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat.
Kelsey JE; Langelier NA; Oriel BS; Reedy C
Psychopharmacology (Berl); 2009 Jan; 201(4):529-39. PubMed ID: 18791705
[TBL] [Abstract][Full Text] [Related]
7. Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease.
Mori A
Int Rev Neurobiol; 2014; 119():87-116. PubMed ID: 25175962
[TBL] [Abstract][Full Text] [Related]
8. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
Jenner P
Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
[TBL] [Abstract][Full Text] [Related]
9. Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
Petzer JP; Petzer A
Curr Med Chem; 2015; 22(8):975-88. PubMed ID: 25544641
[TBL] [Abstract][Full Text] [Related]
10. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
Weiss SM; Benwell K; Cliffe IA; Gillespie RJ; Knight AR; Lerpiniere J; Misra A; Pratt RM; Revell D; Upton R; Dourish CT
Neurology; 2003 Dec; 61(11 Suppl 6):S101-6. PubMed ID: 14663021
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.
Bové J; Serrats J; Mengod G; Cortés R; Tolosa E; Marin C
Exp Brain Res; 2005 Sep; 165(3):362-74. PubMed ID: 15968457
[TBL] [Abstract][Full Text] [Related]
13. Adenosine A(2A) receptors in nonlocomotor features of Parkinson's disease: introduction.
Ongini E
Neurology; 2003 Dec; 61(11 Suppl 6):S72-3. PubMed ID: 14663015
[No Abstract] [Full Text] [Related]
14. Glutathione-Mediated Neuroprotective Effect of Purine Derivatives.
Matsumura N; Aoyama K
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685879
[TBL] [Abstract][Full Text] [Related]
15. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Jones N; Bleickardt C; Mullins D; Parker E; Hodgson R
Brain Res Bull; 2013 Sep; 98():163-9. PubMed ID: 23838432
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic progress--review XX. Drug treatment of Parkinson's disease.
Pall HS; Williams AC; Ramsden DB
J Clin Hosp Pharm; 1986 Aug; 11(4):229-36. PubMed ID: 3531240
[No Abstract] [Full Text] [Related]
17. A
Lambertucci C; Marucci G; Catarzi D; Colotta V; Francucci B; Spinaci A; Varano F; Volpini R
Curr Med Chem; 2022 Aug; 29(28):4780-4795. PubMed ID: 35184706
[TBL] [Abstract][Full Text] [Related]
18. [Is the inhibition of adenosine A(2A) receptors an efficient way of Parkinson's disease treatment?].
Ceiślak M; Komoszyński M
Neurol Neurochir Pol; 2006; 40(3):219-26. PubMed ID: 16794962
[TBL] [Abstract][Full Text] [Related]
19. Caffeine as a neuroprotective adenosine receptor antagonist.
Dall'Igna OP; Souza DO; Lara DR
Ann Pharmacother; 2004 Apr; 38(4):717-8. PubMed ID: 14982979
[No Abstract] [Full Text] [Related]
20. [Caffeine, Chocolate and Adenosine A2A Receptor Antagonists in the Treatment of Parkinson's Disease].
Reichmann H
Fortschr Neurol Psychiatr; 2023 Jun; 91(6):256-261. PubMed ID: 35584767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
